The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.
about
Cytoprotection "gone astray": Nrf2 and its role in cancerTumstatin 185-191 increases the sensitivity of non-small cell lung carcinoma cells to cisplatin by blocking proliferation, promoting apoptosis and inhibiting Akt activation.Dimethyl fumarate and the oleanane triterpenoids, CDDO-imidazolide and CDDO-methyl ester, both activate the Nrf2 pathway but have opposite effects in the A/J model of lung carcinogenesisA 2D-QSAR and Grid-Independent Molecular Descriptor (GRIND) Analysis of Quinoline-Type Inhibitors of Akt2: Exploration of the Binding Mode in the Pleckstrin Homology (PH) DomainFlotillin-2 promotes metastasis of nasopharyngeal carcinoma by activating NF-κB and PI3K/Akt3 signaling pathwaysDistinct Profiles for Mitochondrial t-RNAs and Small Nucleolar RNAs in Locally Invasive and Metastatic Colorectal Cancer.Unique roles of Akt1 and Akt2 in IGF-IR mediated lung tumorigenesis.A novel uPAg-KPI fusion protein inhibits the growth and invasion of human ovarian cancer cells in vitroAkt targeting as a strategy to boost chemotherapy efficacy in non-small cell lung cancer through metabolism suppression.Different functions of AKT1 and AKT2 in molecular pathways, cell migration and metabolism in colon cancer cells.Improved antitumor effect of ionizing radiation in combination with rapamycin for treating nasopharyngeal carcinoma.Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells.Akt1 Stimulates Homologous Recombination Repair of DNA Double-Strand Breaks in a Rad51-Dependent Manner.Bisdemethoxycurcumin sensitizes cisplatin-resistant lung cancer cells to chemotherapy by inhibition of CA916798 and PI3K/AKT signaling.
P2860
Q28393784-08F478FF-3636-4058-8C3A-014B3F20D256Q35784481-3896E2C8-DB47-4C1F-8AFF-AD3F0C35D5A3Q36067904-19FCD443-6C1E-4B4A-9BBA-53F788793506Q36236507-F99A8788-7EA4-4A8B-ADCB-F25EB79A5D01Q36288650-35002700-7B58-4BC2-834D-BD7E998B2B28Q36535386-886274FA-6345-4CE3-9FA0-CFF53B0A9E20Q36772120-DB353355-2AB8-44AF-AC87-40CD8D95EEAAQ36791190-2DB91327-1001-41DB-B9B2-4E4B791CC9E4Q37717138-030652B4-160A-4CCE-86B8-EE4FE9043505Q38729538-2BD3BB33-6398-4363-A208-DFC2ACBC7BB6Q40979448-C44F7CCE-153F-450F-9EBF-1DFD835FEAA7Q42292341-B061CEFD-BD9E-4AFC-B9B6-99BA3F8FBC9CQ47383621-DBB1D375-D48F-4E4F-80DE-DC585499D3D0Q47843337-C4FB31E6-0F4D-42AD-8BC2-2123A8AB4B0B
P2860
The role of the dysfunctional akt-related pathway in cancer: establishment and maintenance of a malignant cell phenotype, resistance to therapy, and future strategies for drug development.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The role of the dysfunctional ...... rategies for drug development.
@en
type
label
The role of the dysfunctional ...... rategies for drug development.
@en
prefLabel
The role of the dysfunctional ...... rategies for drug development.
@en
P2860
P356
P1433
P1476
The role of the dysfunctional ...... rategies for drug development.
@en
P2093
Gaetano Romano
P2860
P304
P356
10.1155/2013/317186
P577
2013-12-05T00:00:00Z